A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma

Aún no traducido Aún no traducido
Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2009
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma medications. The study will look at different doses of mepolizumab in comparison to a placebo.
Epistemonikos ID: f67224126bd5fe5b6ead6750a6b7ff320c7d1ac4
First added on: Sep 14, 2017